Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00418574

Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA)

A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy

Sponsor: Menarini Group

Conditions Ovarian Cancer

Interventions Abagovomab Placebo

Updated 9 times since 2017 Last updated: Nov 17, 2011 Started: Dec 31, 2006 Primary completion: Dec 31, 2010 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

No benefit on primary end point (RFS); no rationale to collect survival data

Other terminated trials from Menarini Group

More terminations from Menarini Group

Other Ovarian Cancer trials with similar outcome

Browse all Ovarian Cancer trials

Listed as NCT00418574, this PHASE2/PHASE3 trial focuses on Ovarian Cancer and remains terminated or withdrawn. Sponsored by Menarini Group, it has been updated 9 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2_PHASE3

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2_PHASE3

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Menarini Group

Data source: Menarini Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aalst, Belgium , Badalona, Spain , Baltimore, United States , Barcelona, Spain , Bari, Italy , Berlin, Germany , Bologna, Italy , Bonn, Germany , Bordeaux, France and 119 more locations